The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 07, 2020

Filed:

Mar. 29, 2016
Applicant:

Iucf-hyu (Industry-university Cooperation Foundation Hanyang University), Seoul, KR;

Inventors:

Chul Geun Kim, Seoul, KR;

Min Young Kim, Incheon, KR;

Chan Gil Kim, Chungju-si, KR;

Ho Chul Kang, Suwon-si, KR;

Ji Hyung Chae, Seoul, KR;

Su Jae Lee, Seoul, KR;

Eun Jung Baek, Seoul, KR;

Chae Ok Yun, Seoul, KR;

Jin Won Lee, Seoul, KR;

Young Su Lim, Jeonju-si, KR;

Je Min Choi, Seoul, KR;

Dae Hyun Ha, Seoul, KR;

Hyung Sik Won, Chungju-si, KR;

Seung Han Son, Incheon, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 9/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/00 (2006.01); A23L 33/18 (2016.01); A23L 33/00 (2016.01);
U.S. Cl.
CPC ...
C07K 7/06 (2013.01); A23L 33/18 (2016.08); A23L 33/40 (2016.08); A61K 9/0056 (2013.01); C07K 14/00 (2013.01); A23V 2002/00 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/10 (2013.01);
Abstract

A peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1: Asn-Tyr-Pro-Gln-Arg-Pro, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient are disclosed. When cancer cells are treated with the peptide and the pharmaceutical composition containing the same, the peptide can specifically bind to CP2c by passing, with very high stability, through the cell membrane and can inhibit the DNA binding ability of CP2c, thereby disturbing CP2c-mediated cancer cell-specific transcriptional activity through the inhibition of CP2c activity. Thus, the peptide and pharmaceutical composition containing the same can be effectively used for specifically treating only cancer cells and can be utilized for cancer prevention and as a dietary supplement additive therefor.


Find Patent Forward Citations

Loading…